NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented ...

The company didn't quite meet expectations for either trailing results or full-year guidance. Cancer drug developer Y-mAbs Therapeutics (YMAB -11.24%) didn't exactly kick off the stock trading week on a high note. The company's shares closed the day more than 11% lower in price, following the release of its latest set of quarterly results. That contrasted unfavorably with the performance of the bellwether S&P 500 index, which flatlined that session. A double miss for the second quarter Y-mAbs is a commercia ...

simonkr Topline Summary and Update Y-mAbs Therapeutics (NASDAQ:YMAB) has maintained something of a holding pattern in terms of market valuation after my last article published in May 2024. Now, we've seen some updates coming out of summer meetings, as well as new financial filings for the company. Still sitting at a market cap of nearly $500 million, YMAB continues to be priced in line with a mid-stage clinical biotech, as opposed to being a commercial-stage entity, and today I want to take a look to see if ...

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -61.54%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.15, delivering a surprise of -25%. Over the last four quarters, the company h ...

Reported Total DANYELZA Net Product Revenues of $22.8 million for the second quarter of 2024, representing a 10% YoY increase Continued geographic expansion of DANYELZA with new market revenues recorded in the second quarter from Brazil and Mexico; DANYELZA now approved in Hong Kong Part A of Phase 1 GD2-SADA Trial from novel SADA-PRIT radiotherapy platform expected to be completed in the fourth quarter of 2024 Appointed Peter Pfreundschuh as the new Chief Financial Officer and radiopharma industry veteran ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences: Wedbush PacGrow Healthcare Conference Date: Tuesday, August 13, 2024 Location: New York, NY Format: Investo ...

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB): TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED THE STOCK OF Y-MABS THERAPEUTICS, INC. ("Y-MABS") BETWEEN OCTOBER 6, 2020 AND OCTOBER 28, 2022, BOTH DATES INCLUSIVE. You are receiving this N ...

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "YmAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer. Mr. Pfreundschuh p ...

Mr. Pfreundschuh will be based in Y-mAbs' New York and New Jersey offices. Forward-Looking Statements DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc. "I am thrilled to join the Y-mAbs team during this pivotal time for the company," said Mr. Pfreundschuh. "With a solid financial foundation fueled by the growing commercial success of DANYELZA® on a global scale, I believe Y-mAbs is well positioned to further advance our SADA-PRIT technology platform and materially change the way w ...